Literature DB >> 21412368

Urine drug testing in chronic pain.

Paul J Christo1, Laxmaiah Manchikanti, Xiulu Ruan, Michael Bottros, Hans Hansen, Daneshvari R Solanki, Arthur E Jordan, James Colson.   

Abstract

Therapeutic use, overuse, abuse, and diversion of controlled substances in managing chronic non-cancer pain continue to be an issue for physicians and patients. The challenge is to eliminate or significantly curtail abuse of controlled prescription drugs while still assuring the proper treatment of those patients. Some physicians are apprehensive regarding the use of chronic opioid therapy in chronic non-cancer pain due to a perceived lack of proven evidence, the misuse of opioids, tolerance, dependence, and hyperalgesia. However, others have criticized the underuse of opioids, resulting in the undertreatment of pain. It has been the convention that federal, state, and local governments; professional associations; as well as pharmaceutical companies, physicians, accrediting bodies, medical licensure boards, and the public all share responsibility for preventing abuse of controlled prescription drugs. To overcome the critical challenge of eliminating or significantly curtailing abuse of controlled prescription drugs and at the same time assuring the appropriate treatment for those patients who can be helped by these medications, it is crucial to practice adherence or compliance monitoring of opioid therapy. Compliance monitoring has been shown to be crucial in delivering proper opioid therapy and preserving this therapy for the future. Urine drug testing (UDT) is considered one of the mainstays of adherence monitoring in conjunction with prescription monitoring programs and other screening tools, however, UDT is associated with multiple limitations secondary to potential pitfalls related to drug metabolism, reliability of the tests, and the knowledge of the pain physician. UDT is a widely available and familiar method for monitoring opioid use in chronic pain patients. UDT can provide tools for tracking patient compliance and expose possible drug misuse and abuse. UDT is one of the major tools of adherence monitoring in the assessment of the patient's predisposition to, and patterns of, drug misuse/abuse--a vital first step towards establishing and maintaining the safe and effective use of opioid analgesics in the treatment of chronic pain. This comprehensive review provides the role of UDT in monitoring chronic opioid therapy along with reliability and accuracy, appropriate use, overuse, misuse, and abuse.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412368

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  32 in total

1.  Peripheral nerve stimulation for trigeminal neuropathic pain.

Authors:  David A Stidd; Adam L Wuollet; Kirk Bowden; Theodore Price; Amol Patwardhan; Steve Barker; Martin E Weinand; Jeffrey Annabi; Emil Annabi
Journal:  Pain Physician       Date:  2012 Jan-Feb       Impact factor: 4.965

2.  Use of Immersive Learning and Simulation Techniques to Teach and Research Opioid Prescribing Practices.

Authors:  Marissa S Heirich; Lanja S Sinjary; Maisa S Ziadni; Sandra Sacks; Alexandra S Buchanan; Sean C Mackey; Jordan L Newmark
Journal:  Pain Med       Date:  2019-03-01       Impact factor: 3.750

Review 3.  Review of the Current State of Urine Drug Testing in Chronic Pain: Still Effective as a Clinical Tool and Curbing Abuse, or an Arcane Test?

Authors:  Krishnan Chakravarthy; Aneesh Goel; George M Jeha; Alan David Kaye; Paul J Christo
Journal:  Curr Pain Headache Rep       Date:  2021-02-17

4.  Toxicologic testing for opiates: understanding false-positive and false-negative test results.

Authors:  Christopher J Keary; Ying Wang; Jonathan R Moran; Lazaro V Zayas; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2012-07-26

Review 5.  Management of pain with comorbid substance abuse.

Authors:  Daniel Krashin; Natalia Murinova; Jane Ballantyne
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

6.  They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain.

Authors:  Joanna L Starrels; Aaron D Fox; Hillary V Kunins; Chinazo O Cunningham
Journal:  J Gen Intern Med       Date:  2012-07-20       Impact factor: 5.128

7.  Profiles of Urine Drug Test in Clinical Pain Patients vs Pain Research Study Subjects.

Authors:  Cheng-ting Lee; Trang T Vo; Abigail S Cohen; Shihab Ahmed; Yi Zhang; Jianren Mao; Lucy Chen
Journal:  Pain Med       Date:  2016-01-28       Impact factor: 3.750

8.  Trends in Urine Drug Testing Among Long-term Opioid Users, 2012-2018.

Authors:  Shaden A Taha; Jordan R Westra; Mukaila A Raji; Yong F Kuo
Journal:  Am J Prev Med       Date:  2020-12-05       Impact factor: 5.043

9.  Primary care providers' experiences with urine toxicology tests to manage prescription opioid misuse and substance use among chronic noncancer pain patients in safety net health care settings.

Authors:  Rachel Ceasar; Jamie Chang; Kara Zamora; Emily Hurstak; Margot Kushel; Christine Miaskowski; Kelly Knight
Journal:  Subst Abus       Date:  2016       Impact factor: 3.716

10.  Evaluation of a Newly Formulated Enzyme Immunoassay for the Detection of Hydrocodone and Hydromorphone in Pain Management Compliance Testing.

Authors:  Renata Nascimento; Alphonse Poklis; Carl E Wolf
Journal:  J Anal Toxicol       Date:  2016-08-25       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.